In response, Dave presents a study to be discussed at the 2024 American Society of Hematology (ASH) Annual Meeting and ...
Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia ...
Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools ...
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach.
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection ...
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...
Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.
Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.
CRB-701 has gained FDA fast track status for the treatment of adult patients with relapsed/refractory metastatic cervical ...